Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical hodgkin lymphoma

Journal of Clinical Oncology

Volumn 31, Issue 6, 2013, Pages 692-700

  Scott, David W ^a   Chan, Fong Chun ^a   Hong, Fangxin ^a   Rogic, Sanja ^a   Tan, King L ^a   Meissner, Barbara ^a   Ben Neriah, Susana ^a   Boyle, Merrill ^a   Kridel, Robert ^a   Telenius, Adele ^a   Woolcock, Bruce W ^a   Farinha, Pedro ^a   Fisher, Richard I ^a   Rimsza, Lisa M ^a   Bartlett, Nancy L ^a   Cheson, Bruce D ^a   Shepherd, Lois E ^a   Advani, Ranjana H ^a   Connors, Joseph M ^a   Kahl, Brad S ^a   Gordon, Leo I ^a   Horning, Sandra J ^a   Steidl, Christian ^a   Gascoyne, Randy D ^a   more..

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; FORMALDEHYDE; PARAFFIN; PREDNISONE; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DISEASE REGISTRY; FEMALE; GENE EXPRESSION; HIGH RISK POPULATION; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; TISSUE FIXATION; TREATMENT FAILURE; TUMOR BIOPSY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; FEMALE; FIXATIVES; FORMALDEHYDE; GENE EXPRESSION PROFILING; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PARAFFIN EMBEDDING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

EID: 84875743842     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.4589     Document Type: Article

References (30)

1. Borchmann P, Engert A: The past: What have we learned in the past decade. Hematology Am Soc Hematol Educ Program 2010:100-107, 2010
2. Diehl V, Franklin J, Pfreundschuh M, et al: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348:2386-2395, 2003 (Pubitemid 36682817)
3. Engert A, Diehl V, Franklin J, et al: Escalateddose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27:4548-4554, 2009
4. Viviani S, Zinzani PL, Rambaldi A, et al: ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med 365: 203-212, 2011
5. Moccia AA, Donaldson J, Chhanabhai M, et al: International Prognostic Score in advanced-stage Hodgkin's lymphoma: Altered utility in the modern era. J Clin Oncol 30:3383-3388, 2012
6. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339:1506-1514, 1998
7. Steidl C, Connors JM, Gascoyne RD: Molecular pathogenesis of Hodgkin's lymphoma: Increasing evidence of the importance of the microenvironment. J Clin Oncol 29:1812-1826, 2011
8. Steidl C, Lee T, Shah SP, et al: Tumorassociated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 362:875-885, 2010
9. Geiss GK, Bumgarner RE, Birditt B, et al: Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 26:317-325, 2008 (Pubitemid 351355126)
10. Gordon LI, Hong F, Fisher RI, et al: A randomized phase III trial of ABVD vs. Stanford V -/- radiation therapy in locally extensive and advanced stage Hodgkin's lymphoma: An intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). Blood 116:415, 2010 (abstr)
11. Swerdlow SH, Campo E, Harris NL, et al: World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed 4). Lyon, France, IARC Press, 2008
12. Uno H, Cai T, Pencina MJ, et al: On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med 30:1105-1117, 2011
13. Heagerty PJ, Lumley T, Pepe MS: Timedependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56:337-344, 2000 (Pubitemid 30422619)
14. Benjamini Y, Hochberg Y: Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc B 57:289-300, 1995
15. Gray RJ: Weighted analyses for cohort sampling designs. Lifetime Data Anal 15:24-40, 2009
16. Devilard E, Bertucci F, Trempat P, et al: Gene expression profiling defines molecular subtypes of classical Hodgkin's disease. Oncogene 21:3095- 3102, 2002 (Pubitemid 34522911)
17. Sánchez-Aguilera A, Montalbán C, de la Cueva P, et al: Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 108:662-668, 2006 (Pubitemid 44061368)
18. Sánchez-Espiridion B, Sánchez-Aguilera A, Montalbán C, et al: A TaqMan low-density array to predict outcome in advanced Hodgkin's lymphoma using paraffin-embedded samples. Clin Cancer Res 15:1367-1375, 2009
19. Chetaille B, Bertucci F, Finetti P, et al: Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 113:2765-2775, 2009
20. Reis PP, Waldron L, Goswami RS, et al: mRNA transcript quantification in archival samples using multiplexed, color-coded probes. BMC Biotechnol 11:46, 2011
21. Steidl C, Farinha P, Gascoyne RD: Macrophages predict treatment outcome in Hodgkin's lymphoma. Haematologica 96:186-189, 2011
22. Kamper P, Bendix K, Hamilton-Dutoit S, et al: Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica 96: 269-276, 2011
23. Diepstra A, van Imhoff GW, Schaapveld M, et al: Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcomes in older adult patients. J Clin Oncol 27: 3815-3821, 2009
24. Jarrett RF,Stark GL, White J, et al: Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: A population-based study. Blood 106:2444-2451, 2005 (Pubitemid 41510819)
25. Keegan TH, Glaser SL, Clarke CA, et al: Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: A population-based study. J Clin Oncol 23:7604-7613, 2005 (Pubitemid 46291824)
26. Alvaro T,Lejeune M, Salvadó MT, et al: Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 11:1467-1473, 2005 (Pubitemid 40315228)
27. Sa'nchez-Espiridio'n B, Montalba'n C, Ló pez A, et al: A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. Blood 116:e12-e17, 2010
28. Oudejans JJ, Jiwa NM, Kummer JA, et al: Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood 89:1376-1382, 1997 (Pubitemid 27080002)
29. Guisado-Vasco P, Arranz-Saez R, Canales M, et al: Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series. Leuk Lymphoma 53:812-819, 2012
30. Borchmann P, Engert A, Diehl V: Chemotherapy: Hodgkin lymphoma - Absence of evidence not evidence of absence! Nat Rev Clin Oncol 8:636-637, 2011